• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
ROR1 expression in ovarian cancer patients and its association with chemotherapy response and prognosis.卵巢癌患者中ROR1的表达及其与化疗反应和预后的关系。
Int J Clin Exp Pathol. 2025 May 15;18(5):179-190. doi: 10.62347/EHAI6164. eCollection 2025.
2
Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.卵巢癌干细胞表达ROR1，它可成为抗癌干细胞治疗的靶点。
Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17266-71. doi: 10.1073/pnas.1419599111. Epub 2014 Nov 19.
3
ROR1 expression correlated with poor clinical outcome in human ovarian cancer.ROR1表达与人类卵巢癌的不良临床预后相关。
Sci Rep. 2014 Jul 24;4:5811. doi: 10.1038/srep05811.
4
Meta-Analysis of Survival Effects of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1).受体酪氨酸激酶样孤儿受体 1（ROR1）生存效应的荟萃分析。
Medicina (Kaunas). 2022 Dec 17;58(12):1867. doi: 10.3390/medicina58121867.
5
A fully chimeric IgG antibody for ROR1 suppresses ovarian cancer growth in vitro and in vivo.一种完全嵌合的 ROR1 IgG 抗体可抑制卵巢癌的体内外生长。
Biomed Pharmacother. 2019 Nov;119:109420. doi: 10.1016/j.biopha.2019.109420. Epub 2019 Sep 16.
6
Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues.人癌组织与正常组织中ROR1蛋白表达分析
Clin Cancer Res. 2017 Jun 15;23(12):3061-3071. doi: 10.1158/1078-0432.CCR-16-2083. Epub 2016 Nov 16.
7
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
8
Antitumor activity of a newly developed monoclonal antibody against ROR1 in ovarian cancer cells.一种新开发的抗ROR1单克隆抗体在卵巢癌细胞中的抗肿瘤活性。
Oncotarget. 2017 Oct 7;8(55):94210-94222. doi: 10.18632/oncotarget.21618. eCollection 2017 Nov 7.
9
The antibody-drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models.靶向ROR1的抗体药物偶联物NBE-002在高级别浆液性卵巢癌临床前模型中具有活性。
Ther Adv Med Oncol. 2025 Apr 21;17:17588359251332471. doi: 10.1177/17588359251332471. eCollection 2025.
10
Evaluation of the prognostic significance of receptor tyrosine kinase-like orphan receptor 1 (ROR1) in lung carcinoma and its relation to lymphangiogenesis and epithelial mesenchymal transition.评估受体酪氨酸激酶样孤儿受体1（ROR1）在肺癌中的预后意义及其与淋巴管生成和上皮间质转化的关系。
Pathol Res Pract. 2023 Aug;248:154703. doi: 10.1016/j.prp.2023.154703. Epub 2023 Jul 20.

本文引用的文献

1
Novel humanized monoclonal antibodies against ROR1 for cancer therapy.针对癌症治疗的新型人源化抗 ROR1 单克隆抗体。
Mol Cancer. 2024 Aug 13;23(1):165. doi: 10.1186/s12943-024-02075-y.
2
Discovery of Novel Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) Inhibitors for Cancer Treatment.新型受体酪氨酸激酶样孤儿受体 1（ROR1）抑制剂的发现及其在癌症治疗中的应用。
J Med Chem. 2024 Jul 11;67(13):10655-10686. doi: 10.1021/acs.jmedchem.4c00175. Epub 2024 Jun 24.
3
Heterogeneous Profile of ROR1 Protein Expression across Tumor Types.跨肿瘤类型的ROR1蛋白表达的异质性概况。
Cancers (Basel). 2024 May 15;16(10):1874. doi: 10.3390/cancers16101874.
4
Dihydroartemisinin inhibits tumor progress via blocking ROR1-induced STAT3-activation in non-small cell lung cancer.双氢青蒿素通过阻断非小细胞肺癌中 ROR1 诱导的 STAT3 激活来抑制肿瘤进展。
Int Immunopharmacol. 2024 May 30;133:112157. doi: 10.1016/j.intimp.2024.112157. Epub 2024 Apr 27.
5
Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer.贝伐珠单抗联合化疗治疗铂耐药卵巢癌的真实世界结局。
Gynecol Oncol. 2024 May;184:51-56. doi: 10.1016/j.ygyno.2024.01.027. Epub 2024 Jan 28.
6
Clinical and translational advances in ovarian cancer therapy.卵巢癌治疗的临床和转化进展。
Nat Cancer. 2023 Sep;4(9):1239-1257. doi: 10.1038/s43018-023-00617-9. Epub 2023 Aug 31.
7
Evaluation of the prognostic significance of receptor tyrosine kinase-like orphan receptor 1 (ROR1) in lung carcinoma and its relation to lymphangiogenesis and epithelial mesenchymal transition.评估受体酪氨酸激酶样孤儿受体1（ROR1）在肺癌中的预后意义及其与淋巴管生成和上皮间质转化的关系。
Pathol Res Pract. 2023 Aug;248:154703. doi: 10.1016/j.prp.2023.154703. Epub 2023 Jul 20.
8
ROR1-STAT3 signaling contributes to ovarian cancer intra-tumor heterogeneity.ROR1-STAT3信号传导促成卵巢癌肿瘤内异质性。
Cell Death Discov. 2023 Jul 3;9(1):222. doi: 10.1038/s41420-023-01527-6.
9
ROR1: an orphan becomes apparent.ROR1：一个孤儿变得明显。
Blood. 2022 Oct 6;140(14):1583-1591. doi: 10.1182/blood.2021014760.
10
New insights into the molecular mechanisms of ROR1, ROR2, and PTK7 signaling from the proteomics and pharmacological modulation of ROR1 interactome.从 ROR1 相互作用组的蛋白质组学和药理学调节中获得关于 ROR1、ROR2 和 PTK7 信号转导的分子机制的新见解。
Cell Mol Life Sci. 2022 May 4;79(5):276. doi: 10.1007/s00018-022-04301-6.

卵巢癌患者中ROR1的表达及其与化疗反应和预后的关系。

ROR1 expression in ovarian cancer patients and its association with chemotherapy response and prognosis.

作者信息

Zhang Yan, Wang Wei, Xu Lian, Huang Liujing, Qin Tian, Kang Ling, Huang Qin

机构信息

Department of Pathology, West China Second University Hospital, Sichuan University Chengdu 610000, Sichuan, PR China.

Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, Sichuan University Chengdu 610000, Sichuan, PR China.

出版信息

Int J Clin Exp Pathol. 2025 May 15;18(5):179-190. doi: 10.62347/EHAI6164. eCollection 2025.

DOI:10.62347/EHAI6164
PMID:40519318
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12163482/
Abstract

OBJECTIVE

To investigate the expression of receptor tyrosine kinase-like orphan receptor 1 (ROR1) in ovarian cancer tissues and its correlation with clinicopathologic features, chemotherapy sensitivity, and prognosis in patients with ovarian cancer.

METHODS

Paraffin tissue blocks were collected from 227 ovarian cancer patients, and immunohistochemical (IHC) staining was performed to analyze the expression of ROR1. The associations between ROR1 expression and clinicopathologic features, treatment response, and prognosis were evaluated.

RESULTS

ROR1 expression and tumor load: higher expression of ROR1 was associated with a heavier tumor load in ovarian cancer patients. ROR1 and chemotherapy: the expression of ROR1 was significantly higher in patients who underwent interval debulking surgery (IDS) compared to primary debulking surgery (PDS) and subsequent chemotherapy (SSC). This suggests that chemotherapy may promote increased ROR1 expression in tumor tissues. Additionally, a trend of higher ROR1 expression was observed in platinum-sensitive patients. Nuclear expression in clear cell ovarian cancer: positive nuclear expression of ROR1 was unexpectedly detected in clear cell ovarian cancer, suggesting a link between ROR1 nuclear translocation and poor prognosis.

CONCLUSION

ROR1 expression may be related to treatment strategy and history of platinum-based chemotherapy in ovarian cancer patients. Targeting ROR1 could represent a promising therapeutic strategy for the treatment of ovarian cancer. Further studies are needed to elucidate the role of ROR1 nuclear translocation in prognosis.

摘要

目的

探讨受体酪氨酸激酶样孤儿受体1（ROR1）在卵巢癌组织中的表达及其与卵巢癌患者临床病理特征、化疗敏感性和预后的相关性。

方法

收集227例卵巢癌患者的石蜡组织块，采用免疫组织化学（IHC）染色分析ROR1的表达。评估ROR1表达与临床病理特征、治疗反应和预后之间的关联。

结果

ROR1表达与肿瘤负荷：ROR1表达较高与卵巢癌患者肿瘤负荷较重相关。ROR1与化疗：与初次肿瘤细胞减灭术（PDS）及后续化疗（SSC）相比，接受间歇性肿瘤细胞减灭术（IDS）的患者ROR1表达显著更高。这表明化疗可能促进肿瘤组织中ROR1表达增加。此外，在铂敏感患者中观察到ROR1表达有升高趋势。透明细胞卵巢癌中的核表达：在透明细胞卵巢癌中意外检测到ROR1核阳性表达，提示ROR1核易位与预后不良之间存在关联。

结论

ROR1表达可能与卵巢癌患者的治疗策略及铂类化疗史有关。靶向ROR1可能是治疗卵巢癌的一种有前景的治疗策略。需要进一步研究阐明ROR1核易位在预后中的作用。